Cat. No.: HY-15287

Nelfinavir

(Synonyms: AG1341)

18 Cited Publications

Avis client

Based on 18 publication(s) in Google Scholar

Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (K_i=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.64%
CAS No.: 159989-64-7
Formule: C₃₂H₄₅N₃O₄S
Masse moléculaire:567.78

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Nelfinavir Chemical Structure

CAS No.: 159989-64-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (18)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (K_i=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent^[1]^[2]^[3].

IC₅₀ & Target^[3]

HIV-1

Voir tous les produits spécifiques à Isoform HIV :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	IC₅₀	1.4 μM Compound: Nelfinavir	TP_TRANSPORTER: inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 5 uM) in Caco-2 cells TP_TRANSPORTER: inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 5 uM) in Caco-2 cells	[PMID: 10820137]
CCRF-CEM	EC₅₀	100 nM Compound: NFV	Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay	[PMID: 17576848]
CCRF-CEM	EC₅₀	177 nM Compound: NFV	Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay	[PMID: 17576848]
CCRF-CEM	EC₅₀	199 nM Compound: NFV	Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay	[PMID: 17576848]
CCRF-CEM	EC₅₀	281 nM Compound: NFV	Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay	[PMID: 17576848]
CEM-SS	ED₅₀	0.03 μM Compound: nelfinavir	Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay	[PMID: 15217281]
CEM-SS	IC₅₀	2 nM Compound: nelfinavir	Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as reverse transcriptase activity after 5 days by MTT assay Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as reverse transcriptase activity after 5 days by MTT assay	[PMID: 17950955]
HEK293	IC₅₀	12.5 μM Compound: Nelfinavir	TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation in BCRP-expressing HEK cells TP_TRANSPORTER: increase in mitoxantrone intracellular accumulation in BCRP-expressing HEK cells	[PMID: 15007102]
HEK293	EC₅₀	5.8 nM Compound: NFV	Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay	[PMID: 17638694]
HeLa	IC₅₀	21.8 μM Compound: Nelfinavir	TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in OCT1-expressing HeLa cells TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in OCT1-expressing HeLa cells	[PMID: 10681378]
HeLa	EC₅₀	>1 μM Compound: NFV	Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay	[PMID: 17646410]
HeLa	EC₅₀	>1 μM Compound: NFV	Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay	[PMID: 17646410]
HeLa	EC₅₀	>1 μM Compound: NFV	Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	0.013 μM Compound: NFV	Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	0.016 μM Compound: NFV	Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	0.038 μM Compound: NFV	Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HepG2	CC₅₀	7.4 μM Compound: Nelfinavir	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 5 days by XTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 5 days by XTT assay	10.1039/C1MD00147G
LLC-PK1	IC₅₀	2.3 μM Compound: Nelfinavir	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	2.3 μM Compound: Nelfinavir	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	3.4 μM Compound: Nelfinavir	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	3.4 μM Compound: Nelfinavir	TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells	[PMID: 12699389]
MDCK-II	IC₅₀	19.9 μM Compound: NFV	Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells	[PMID: 17664327]
MOLT-4	EC₅₀	0.029 μM Compound: Nelfinavir	Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay	[PMID: 18316521]
MT2	IC₅₀	10 nM Compound: NFV	Antiviral activity against HIV1 LAI isolate in human MT2 cells Antiviral activity against HIV1 LAI isolate in human MT2 cells	[PMID: 16913714]
MT2	IC₅₀	20 nM Compound: NFV	Antiviral activity against HIV2 EHO isolate in human MT2 cells Antiviral activity against HIV2 EHO isolate in human MT2 cells	[PMID: 16913714]
MT2	CC₅₀	8.1 μM Compound: nelfinavir, NFV	Cytotoxicity against human MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay Cytotoxicity against human MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT2	EC₅₀	0.03 μM Compound: nelfinavir, NFV	Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT2	EC₅₀	0.032 μM Compound: nelfinavir, NFV	Antiviral activity against HIV1 LAI in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against HIV1 LAI in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT2	EC₅₀	0.24 μM Compound: nelfinavir, NFV	Antiviral activity against HIV2 ROD in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against HIV2 ROD in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT2	EC₅₀	0.023 μM Compound: NFV	Antiviral activity against HIV1 LAI infected in human MT2 cells after 7 days by MTT assay Antiviral activity against HIV1 LAI infected in human MT2 cells after 7 days by MTT assay	[PMID: 18955518]
MT2	CC₅₀	19.1 μM Compound: Nelfinavir	Cytotoxicity against human MT2 cells assessed as reduction in cell viability after 5 days by XTT assay Cytotoxicity against human MT2 cells assessed as reduction in cell viability after 5 days by XTT assay	10.1039/C1MD00147G
MT2	EC₅₀	4.9 nM Compound: Nelfinavir	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as virus-induced cytopathic effect after 5 days by XTT assay Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as virus-induced cytopathic effect after 5 days by XTT assay	10.1039/C1MD00147G
MT4	IC₅₀	0.05 μM Compound: Nelfinavir	Compound was evaluated for its antiviral inhibition in MT-4 cell culture Compound was evaluated for its antiviral inhibition in MT-4 cell culture	[PMID: 10866371]
MT4	ED₅₀	0.02 μM Compound: Nelfinavir	Anti-HIV-1 activity against Wild type virus in MT-4 cells Anti-HIV-1 activity against Wild type virus in MT-4 cells	[PMID: 11543677]
MT4	ED₅₀	0.07 μM Compound: Nelfinavir	Anti-HIV-1 activity against mutant HIV-1 in MT-4 cells (mutation selected with compound 1) Anti-HIV-1 activity against mutant HIV-1 in MT-4 cells (mutation selected with compound 1)	[PMID: 11543677]
MT4	ED₅₀	0.11 μM Compound: Nelfinavir	Anti-HIV-1 activity against mutant HIV-1 in MT-4 cells (mutation selected with ritonavir) Anti-HIV-1 activity against mutant HIV-1 in MT-4 cells (mutation selected with ritonavir)	[PMID: 11543677]
MT4	ED₅₀	0.12 μM Compound: Nelfinavir	Anti-HIV-1 activity against mutant HIV-1 in MT-4 cells (mutation selected with saquinavir) Anti-HIV-1 activity against mutant HIV-1 in MT-4 cells (mutation selected with saquinavir)	[PMID: 11543677]
MT4	ED₅₀	2.44 μM Compound: Nelfinavir	Anti-HIV-1 activity against mutant HIV-1 in MT-4 cells (mutation selected with nelfinavir) Anti-HIV-1 activity against mutant HIV-1 in MT-4 cells (mutation selected with nelfinavir)	[PMID: 11543677]
MT4	IC₅₀	320 nM Compound: Nelfinavir	Antiviral activity against wild-type HIV virus (HXB2) was determined in MT-4 cell line Antiviral activity against wild-type HIV virus (HXB2) was determined in MT-4 cell line	[PMID: 15013001]
MT4	IC₅₀	450 nM Compound: Nelfinavir	Antiviral activity against PI resistant virus EP13 was determined in MT-4 cell line Antiviral activity against PI resistant virus EP13 was determined in MT-4 cell line	[PMID: 15013001]
MT4	IC₅₀	>1000 nM Compound: Nelfinavir	Antiviral activity against PI resistant virus D545701 was determined in MT-4 cell line Antiviral activity against PI resistant virus D545701 was determined in MT-4 cell line	[PMID: 15013001]
MT4	ED₅₀	0.02 μM Compound: Nelfinavir	Effective dose of compound required to inhibit replication of human immunodeficiency virus type 1 in MT-4 cells Effective dose of compound required to inhibit replication of human immunodeficiency virus type 1 in MT-4 cells	[PMID: 15537350]
MT4	IC₅₀	320 nM Compound: Nelfinavir	Inhibitory concentration against wild type Human immuno deficiency virus (HXB2) was determined in an MT-4 cell line Inhibitory concentration against wild type Human immuno deficiency virus (HXB2) was determined in an MT-4 cell line	[PMID: 15990305]
MT4	IC₅₀	450 nM Compound: Nelfinavir	Inhibitory concentration against wild type Human immuno deficiency virus (EP13) was determined in an MT-4 cell line Inhibitory concentration against wild type Human immuno deficiency virus (EP13) was determined in an MT-4 cell line	[PMID: 15990305]
MT4	IC₅₀	>1000 nM Compound: Nelfinavir	Inhibitory concentration against wild type Human immuno deficiency virus (D545701) was determined in an MT-4 cell line Inhibitory concentration against wild type Human immuno deficiency virus (D545701) was determined in an MT-4 cell line	[PMID: 15990305]
MT4	IC₅₀	320 nM Compound: nelfinavir	Antiviral activity against HIV1 HXB2 in MT4 cells Antiviral activity against HIV1 HXB2 in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	450 nM Compound: nelfinavir	Antiviral activity against HIV1 EP13 in MT4 cells Antiviral activity against HIV1 EP13 in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	>1000 nM Compound: nelfinavir	Antiviral activity against HIV D545701 in MT4 cells Antiviral activity against HIV D545701 in MT4 cells	[PMID: 16458505]
MT4	EC₅₀	>1 μM Compound: nelfinavir, NFV	Antiviral activity against nelfinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against nelfinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT4	EC₅₀	0.033 μM Compound: nelfinavir, NFV	Antiviral activity against HIV1 NL4-3 in MT4 cells by MTT assay Antiviral activity against HIV1 NL4-3 in MT4 cells by MTT assay	[PMID: 17371811]
MT4	EC₅₀	0.08 μM Compound: nelfinavir, NFV	Antiviral activity against HIV1 GRL98065p20 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against HIV1 GRL98065p20 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT4	EC₅₀	0.21 μM Compound: nelfinavir, NFV	Antiviral activity against ritonavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against ritonavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT4	EC₅₀	0.22 μM Compound: nelfinavir, NFV	Antiviral activity against amprenavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against amprenavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT4	EC₅₀	0.27 μM Compound: nelfinavir, NFV	Antiviral activity against atazanavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against atazanavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT4	EC₅₀	0.27 μM Compound: nelfinavir, NFV	Antiviral activity against HIV1 GRL98065p30 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against HIV1 GRL98065p30 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT4	EC₅₀	0.34 μM Compound: nelfinavir, NFV	Antiviral activity against HIV1 GRL98065p40 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against HIV1 GRL98065p40 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT4	EC₅₀	0.47 μM Compound: nelfinavir, NFV	Antiviral activity against idinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against idinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT4	EC₅₀	0.48 μM Compound: nelfinavir, NFV	Antiviral activity against saquinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against saquinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT4	EC₅₀	0.49 μM Compound: nelfinavir, NFV	Antiviral activity against lopinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay Antiviral activity against lopinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay	[PMID: 17371811]
MT4	EC₅₀	16 nM Compound: nelfinavir	Antiviral activity against HIV1 3B in MT4 cells by MTT assay Antiviral activity against HIV1 3B in MT4 cells by MTT assay	[PMID: 17537628]
MT4	EC₅₀	18 nM Compound: NFV	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 17576848]
MT4	EC₅₀	48 nM Compound: NFV	Antiviral activity against HIV2 MS infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 MS infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 17576848]
MT4	CC₅₀	8 μM Compound: NFV	Cytotoxicity against human MT4 cells after 6 days by MTT assay Cytotoxicity against human MT4 cells after 6 days by MTT assay	[PMID: 17638694]
MT4	EC₅₀	0.029 μM Compound: NFV	Antiviral activity against wild type HIV1 NL4-3 infected in MT4 cells after 6 days by MTT assay Antiviral activity against wild type HIV1 NL4-3 infected in MT4 cells after 6 days by MTT assay	[PMID: 17638694]
MT4	EC₅₀	16 nM Compound: nelfinavir, NFV	Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of viral-induced cytopathic effect by MTT method Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of viral-induced cytopathic effect by MTT method	[PMID: 18426195]
MT4	CC₅₀	11 μM Compound: nelfinavir, NFV	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18426195]
MT4	EC₅₀	0.023 μM Compound: nelfinavir	Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.028 μM Compound: nelfinavir	Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.029 μM Compound: nelfinavir	Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.035 μM Compound: nelfinavir	Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.049 μM Compound: nelfinavir	Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.05 μM Compound: nelfinavir	Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.05 μM Compound: nelfinavir	Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.17 μM Compound: nelfinavir	Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	>1 μM Compound: NFV	Antiviral activity against HIV1 NL4-3 harboring L10F/D30N/K45I/A71V/T74S amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of nelfinavir by ELISA Antiviral activity against HIV1 NL4-3 harboring L10F/D30N/K45I/A71V/T74S amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of nelfinavir by ELISA	[PMID: 18955518]
MT4	EC₅₀	0.011 μM Compound: NFV	Antiviral activity against HIV1 NL4-3 harboring L10F/L33F/M46I/I47V/Q58E/V82I/I84V/I85V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of GRL-02031 by E Antiviral activity against HIV1 NL4-3 harboring L10F/L33F/M46I/I47V/Q58E/V82I/I84V/I85V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of GRL-02031 by E	[PMID: 18955518]
MT4	EC₅₀	0.018 μM Compound: NFV	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of p24 gag protein production by ELISA Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of p24 gag protein production by ELISA	[PMID: 18955518]
MT4	EC₅₀	0.17 μM Compound: NFV	Antiviral activity against HIV1 NL4-3 harboring L10F/V32I/M46I/I54M//A71V/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of amprenavir by ELISA Antiviral activity against HIV1 NL4-3 harboring L10F/V32I/M46I/I54M//A71V/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of amprenavir by ELISA	[PMID: 18955518]
MT4	EC₅₀	0.21 μM Compound: NFV	Antiviral activity against HIV1 NL4-3 harboring L23I/K43I/M46I/I50L/G51A/A71V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of atazanavir by ELISA Antiviral activity against HIV1 NL4-3 harboring L23I/K43I/M46I/I50L/G51A/A71V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of atazanavir by ELISA	[PMID: 18955518]
MT4	EC₅₀	0.24 μM Compound: NFV	Antiviral activity against HIV1 NL4-3 harboring M46I/V82F/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of ritonavir by ELISA Antiviral activity against HIV1 NL4-3 harboring M46I/V82F/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of ritonavir by ELISA	[PMID: 18955518]
MT4	EC₅₀	0.32 μM Compound: NFV	Antiviral activity against HIV1 NL4-3 harboring L10I/G48V/I54V/L90M amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of saquinavir by ELISA Antiviral activity against HIV1 NL4-3 harboring L10I/G48V/I54V/L90M amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of saquinavir by ELISA	[PMID: 18955518]
MT4	EC₅₀	0.51 μM Compound: NFV	Antiviral activity against HIV1 NL4-3 harboring L10F/M46I/I54V/V82A amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of Lopinavir by ELISA Antiviral activity against HIV1 NL4-3 harboring L10F/M46I/I54V/V82A amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of Lopinavir by ELISA	[PMID: 18955518]
MT4	EC₅₀	0.65 μM Compound: NFV	Antiviral activity against HIV1 NL4-3 harboring L10F/L24I/M46I/L63P/A71V/G73S/V82T amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of indinavir by ELISA Antiviral activity against HIV1 NL4-3 harboring L10F/L24I/M46I/L63P/A71V/G73S/V82T amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of indinavir by ELISA	[PMID: 18955518]
MT4	EC₅₀	>1 μM Compound: NFV	Antiviral activity against HIV1 expressing protease L10F/D30N/K45I/A71V/T74S mutant infected in human MT4 cells selected at 5 uM of nelfinavir by MTT assay Antiviral activity against HIV1 expressing protease L10F/D30N/K45I/A71V/T74S mutant infected in human MT4 cells selected at 5 uM of nelfinavir by MTT assay	[PMID: 20439612]
MT4	EC₅₀	>1 μM Compound: NFV	Antiviral activity against HIV1 expressing protease L23I/E34Q/K43I/M46I/I50L/G51A/L63P/A71V/V82A/T91A mutant infected in human MT4 cells selected at 5 uM of atazanavir by MTT assay Antiviral activity against HIV1 expressing protease L23I/E34Q/K43I/M46I/I50L/G51A/L63P/A71V/V82A/T91A mutant infected in human MT4 cells selected at 5 uM of atazanavir by MTT assay	[PMID: 20439612]
MT4	EC₅₀	0.045 μM Compound: NFV	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by MTT assay Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by MTT assay	[PMID: 20439612]
MT4	EC₅₀	0.13 μM Compound: NFV	Antiviral activity against HIV1 expressing protease L10I/L24I/M46I/V82I/I84V mutant infected in human MT4 cells selected after 50 passages of GRL-216 by MTT assay Antiviral activity against HIV1 expressing protease L10I/L24I/M46I/V82I/I84V mutant infected in human MT4 cells selected after 50 passages of GRL-216 by MTT assay	[PMID: 20439612]
MT4	EC₅₀	0.22 μM Compound: NFV	Antiviral activity against HIV1 expressing protease L10F/M46M,I/Q61Q mutant infected in human MT4 cells selected at 1 uM of GRL-396 by MTT assay Antiviral activity against HIV1 expressing protease L10F/M46M,I/Q61Q mutant infected in human MT4 cells selected at 1 uM of GRL-396 by MTT assay	[PMID: 20439612]
MT4	EC₅₀	0.29 μM Compound: NFV	Antiviral activity against HIV1 expressing protease L10F/M46I/T91S mutant infected in human MT4 cells selected at 1 uM of GRL-246 by MTT assay Antiviral activity against HIV1 expressing protease L10F/M46I/T91S mutant infected in human MT4 cells selected at 1 uM of GRL-246 by MTT assay	[PMID: 20439612]
MT4	EC₅₀	0.3 μM Compound: NFV	Antiviral activity against HIV1 expressing protease L10F/M46I/I50V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of amprenavir by MTT assay Antiviral activity against HIV1 expressing protease L10F/M46I/I50V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of amprenavir by MTT assay	[PMID: 20439612]
MT4	EC₅₀	0.32 μM Compound: NFV	Antiviral activity against HIV1 expressing protease L10F/M46I/I54V/V82A mutant infected in human MT4 cells selected at 5 uM of Lopinavir by MTT assay Antiviral activity against HIV1 expressing protease L10F/M46I/I54V/V82A mutant infected in human MT4 cells selected at 5 uM of Lopinavir by MTT assay	[PMID: 20439612]
MT4	EC₅₀	0.37 μM Compound: NFV	Antiviral activity against HIV1 expressing protease L10F/M46L/I50V/A71Vmutant infected in human MT4 cells selected at 1 uM of GRL-286 by MTT assay Antiviral activity against HIV1 expressing protease L10F/M46L/I50V/A71Vmutant infected in human MT4 cells selected at 1 uM of GRL-286 by MTT assay	[PMID: 20439612]
MT4	EC₅₀	0.51 μM Compound: NFV	Antiviral activity against HIV1 expressing protease L10I/G48V/I54V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of saquinavir by MTT assay Antiviral activity against HIV1 expressing protease L10I/G48V/I54V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of saquinavir by MTT assay	[PMID: 20439612]
PBMC	IC₅₀	>1000 nM Compound: NFV	Antiviral activity against multi drug-resistant HIV1 ES variant in human PHA-PBMC cells Antiviral activity against multi drug-resistant HIV1 ES variant in human PHA-PBMC cells	[PMID: 16913714]
PBMC	IC₅₀	>1000 nM Compound: NFV	Antiviral activity against multi drug-resistant HIV1 EV variant in human PHA-PBMC cells Antiviral activity against multi drug-resistant HIV1 EV variant in human PHA-PBMC cells	[PMID: 16913714]
PBMC	IC₅₀	>1000 nM Compound: NFV	Antiviral activity against multi drug-resistant HIV1 K variant in human PHA-PBMC cells Antiviral activity against multi drug-resistant HIV1 K variant in human PHA-PBMC cells	[PMID: 16913714]
PBMC	IC₅₀	>1000 nM Compound: NFV	Antiviral activity against multi drug-resistant HIV1 TM variant in human PHA-PBMC cells Antiviral activity against multi drug-resistant HIV1 TM variant in human PHA-PBMC cells	[PMID: 16913714]
PBMC	IC₅₀	14 nM Compound: NFV	Antiviral activity against HIV1 LAI isolate in human PHA-PBMC cells Antiviral activity against HIV1 LAI isolate in human PHA-PBMC cells	[PMID: 16913714]
PBMC	IC₅₀	170 nM Compound: NFV	Antiviral activity against multi drug-resistant HIV1 G variant in human PHA-PBMC cells Antiviral activity against multi drug-resistant HIV1 G variant in human PHA-PBMC cells	[PMID: 16913714]
PBMC	IC₅₀	310 nM Compound: NFV	Antiviral activity against multi drug-resistant HIV1 C variant in human PHA-PBMC cells Antiviral activity against multi drug-resistant HIV1 C variant in human PHA-PBMC cells	[PMID: 16913714]
PBMC	IC₅₀	32 nM Compound: NFV	Antiviral activity against multi drug-resistant HIV1 ET variant in human PHA-PBMC cells Antiviral activity against multi drug-resistant HIV1 ET variant in human PHA-PBMC cells	[PMID: 16913714]
PBMC	IC₅₀	7 nM Compound: NFV	Antiviral activity against HIV1 BA-L isolate in human PHA-PBMC cells Antiviral activity against HIV1 BA-L isolate in human PHA-PBMC cells	[PMID: 16913714]
PBMC	IC₅₀	>1000 nM Compound: NFV	Antiviral activity against multi drug-resistant HIV1 B variant in human PHA-PBMC cells Antiviral activity against multi drug-resistant HIV1 B variant in human PHA-PBMC cells	[PMID: 16913714]
PBMC	EC₅₀	0.25 μM Compound: 4, NFV	Antiviral activity against multidrug-resistant HIV1-C infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay Antiviral activity against multidrug-resistant HIV1-C infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay	[PMID: 26799988]

In Vitro

Nelfinavir (AG1341) (1-10 μM; 48 hours) inhibits the proliferation of multiple myeloma cells^[4].
Nelfinavir inhibits 26S chymotrypsin-like proteasome activity, impairs proliferation and triggers apoptosis of the myeloma cell lines and fresh plasma cells^[4].
Nelfinavir (1-10 μM; 17 hours) induces apoptosis of multiple myeloma cell lines^[4].
Nelfinavir (5 μM; 0-24 hours) decreases the phosphorylation of AKT^[4].
Nelfinavir activates the cleavage of caspase-3, decreases the phosphorylation of AKT, STAT-3, ERK1/2, and activates the pro-apoptotic pathway of the unfolded protein response system^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[4]

Cell Line:

RPMI, LP1, U266, OPM2 and MM1S cells
Concentration:

1, 2, 5, 10 μM
Incubation Time:

48 hours
Result:

Inhibited the proliferation of RPMI, LP1, U266, OPM2 and MM1S cell lines in a dose-dependent manner with an IC₅₀ of 1-5 μM.

Apoptosis Analysis^[4]

Cell Line:

LP1 and U266 cells
Concentration:

1-10 μM
Incubation Time:

17 hours
Result:

Induced a dose-dependent increase in the percentage of annexin V⁺/propidium iodide⁺ cells.

Western Blot Analysis^[4]

Cell Line:

U266 cells
Concentration:

5 μM
Incubation Time:

0-24 hours
Result:

The level of AKT phosphorylation in U266 cells decreased.

In Vivo

Nelfinavir (AG1341) (75 mg/kg; i.p.; 5 days a week for 21 days) decreases multiple myeloma cell growth in NOD/SCID mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD/SCID mice (bearing U266-luc cells)^[4]
Dosage:

75 mg/kg
Administration:

I.p.; 5 days a week for 21 days
Result:

Decreased MM cell growth in NOD/SCID mice.

Chemical Information

CAS No. 159989-64-7
Appearance Solid
Masse moléculaire 567.78
Formule C₃₂H₄₅N₃O₄S
Color White to off-white
SMILES

[H][C@]12C[C@@H](C(NC(C)(C)C)=O)N(C[C@H]([C@@H](NC(C3=C(C)C(O)=CC=C3)=O)CSC4=CC=CC=C4)O)C[C@@]1([H])CCCC2
Synonyms

AG1341
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (18)

All Histological Imaging/StainingBio/Physico-chemical AssayCell Migration/Invasion AssayWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. [Abstract]

2021 May 29;6(1):212. PMID: 34052830
Nat Commun

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. [Abstract]

2020 Sep 4;11(1):4417. PMID: 32887884
Mol Ther Oncol

Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/ SPAM1-armed oncolytic adenovirus Ad5Δ24RGD. [Abstract]

2026 Jan 23;34(1):201137. PMID: 41716467
J Med Chem

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration. [Abstract]

2021 Mar 11;64(5):2725-2738. PMID: 33619967
Cells

Targeting Wnt/β-Catenin Signaling Exacerbates Ferroptosis and Increases the Efficacy of Melanoma Immunotherapy via the Regulation of MITF. [Abstract]

2022 Nov 12;11(22):3580. PMID: 36429010

Nelfinavir purchased from MedChemExpress. Usage Cited in: Cells. 2022 Nov 12;11(22):3580. [Abstract]

Nelfinavir Mesylate (5 µM; 24 h) suppresses expression of MITF in A2058 and A375 cells.
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
Cell Signal

Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors. [Abstract]

2020 Nov:75:109775. PMID: 32916277
Mol Oncol

Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]

2026 Jun 5. PMID: 42246237
Antiviral Res

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. [Abstract]

2022 Jun;202:105311. PMID: 35390430

Nelfinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Jun;202:105311. [Abstract]

Cumulative severity score from H&E-stained slides of lungs from SARS-CoV-2-infected hamsters at 4 dpi treated with vehicle, 15 mg/kg Nelfinavir BID, or 50 mg/kg Nelfinavir BID (Nelfinavir:i.p., twice daily for four consecutive days).

Nelfinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Jun;202:105311. [Abstract]

Representative H&E-stained slides of lungs from vehicle control (top panel) and 50 mg/kg BID Nelfinavir-treated (bottom panel) SARS-CoV-2-infected hamsters at 4 dpi. Top panel: bronchopneumonia centred on a bronchiol (black arrows) in a vehicle-treated hamster (scale bar at 100 μm). Bottom panel: severe interstitial inflammation with mostly PMN and congestion in a Nelfinavir-treated hamster (scale bar at 100 μm). Black arrows indicate bronchiol (insert at higher magnification, scale bar at 50 μm).

Nelfinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Jun;202:105311. [Abstract]

Haematological analysis revealed increases in white blood cell, platelet, and neutrophil counts in Nelfinavir-treated (50 mg/kg, i.p., twice daily for four consecutive days) uninfected animals as compared to the vehicle control.

Nelfinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Jun;202:105311. [Abstract]

The neutrophils of Nelfinavir-treated (50 mg/kg, i.p., twice daily for four consecutive days) animals had a higher granularity intensity (Neut-GI) and a higher reactivity intensity (Neut-RI).

Nelfinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Jun;202:105311. [Abstract]

Nelfinavir (50 μg/ml, 1 h) significantly enhanced the migration of human neutrophils towards the CXCR1 and CXCR2 agonist CXCL8 (5 and 25 ng/ml) in the Boyden microchamber assay in vitro.
Antimicrob Agents Chemother

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2. [Abstract]

2020 Aug 20;64(9):e00872-20. PMID: 32669265
Viruses

A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants. [Abstract]

2022 Jun 23;14(7):1369. PMID: 35891350
PLoS One

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action. [Abstract]

2015 Aug 11;10(8):e0134707. PMID: 26263487
Res Sq

2026 Jun 1.
Patent

US20250123269A1.
bioRxiv

2024 November 03.
bioRxiv

2021 Feb 1.
bioRxiv

2020 May.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (176.12 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7612 mL

8.8062 mL

17.6125 mL

5 mM

0.3522 mL

1.7612 mL

3.5225 mL

10 mM

0.1761 mL

0.8806 mL

1.7612 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 17% Solutol HS-15 in Saline

Solubility: 15.15 mg/mL (26.68 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (286 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Mondal D, et al. Nelfinavir suppresses signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J. 2013 Spring;13(1):76-90. [Content Brief]

[2]. Gills JJ, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that inducesendoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007 Sep 1;13(17):5183-94. [Content Brief]

[3]. Kaldor SW, et al. Nelfinavir mesylate (AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40(24):3979-85. [Content Brief]

[4]. Bono C, et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica. 2012;97(7):1101‐1109. [Content Brief]

[5]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7612 mL	8.8062 mL	17.6125 mL	44.0311 mL
	5 mM	0.3522 mL	1.7612 mL	3.5225 mL	8.8062 mL
	10 mM	0.1761 mL	0.8806 mL	1.7612 mL	4.4031 mL
	15 mM	0.1174 mL	0.5871 mL	1.1742 mL	2.9354 mL
	20 mM	0.0881 mL	0.4403 mL	0.8806 mL	2.2016 mL
	25 mM	0.0704 mL	0.3522 mL	0.7045 mL	1.7612 mL
	30 mM	0.0587 mL	0.2935 mL	0.5871 mL	1.4677 mL
	40 mM	0.0440 mL	0.2202 mL	0.4403 mL	1.1008 mL
	50 mM	0.0352 mL	0.1761 mL	0.3522 mL	0.8806 mL
	60 mM	0.0294 mL	0.1468 mL	0.2935 mL	0.7339 mL
	80 mM	0.0220 mL	0.1101 mL	0.2202 mL	0.5504 mL
	100 mM	0.0176 mL	0.0881 mL	0.1761 mL	0.4403 mL

Keywords

Nelfinavir

18 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Nelfinavir

Anti-Infection Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Rare Diseases Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Protease Inhibitor Library

Mitochondrial Toxicity Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Nelfinavir

Voir tous les produits spécifiques à Isoform HIV

Activité biologique

Chemical Information

Publications (18)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Nelfinavir Related Classifications

HY-15287 Related Classifications